Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 3 studies. This list may not include all unresolved or historical entries.

Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(67%)

Phase Distribution

Ph phase_1
2
67%
Ph phase_2_3
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2/3Combined phases
1(33.3%)

Highest Phase Reached

Phase 2/3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 2/3

Trials by Phase

Phase 12 (66.7%)
Phase 2/31 (33.3%)

Trials by Status

terminated267%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2_3

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

NCT05267574
completedphase_1

A Study of the Safety of REN001 in Patients With McArdle Disease

NCT04226274
terminatedphase_1

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

NCT03862846

Clinical Trials (3)

Showing 3 of 3 trials
NCT05267574Phase 2/3

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

Terminated
NCT04226274Phase 1

A Study of the Safety of REN001 in Patients With McArdle Disease

Completed
NCT03862846Phase 1

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Terminated

All 3 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
3